Related Experiment Videos
The proteasome is a major autoantigen in multiple sclerosis
Isabel Mayo1, Joaquín Arribas, Pablo Villoslada
1Instituto de Investigaciones Biomédicas Alberto Sols, UAM-CSIC, Facultad de Medicina, UAM, Servicio de Inmunología, Hospital Universitario La Paz, Madrid, Spain.
Brain : a Journal of Neurology
|November 14, 2002
Summary
Autoantibodies targeting the proteasome are prevalent in multiple sclerosis patients, suggesting a potential diagnostic marker. This finding also points to broader immune system dysregulation in the disease.
Area of Science:
- Immunology
- Neuroscience
- Proteasome Biology
Background:
- Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system (CNS), with the autoimmune response typically targeting myelin components.
- The etiology of MS remains largely unknown, necessitating the identification of novel biomarkers and pathogenic mechanisms.
Purpose of the Study:
- To investigate the proteasome as a potential target for autoantibodies in multiple sclerosis (MS).
- To determine the prevalence of anti-proteasome autoantibodies in MS patients and compare it to other inflammatory conditions.
- To explore the role of proteasome subunits in T-cell proliferation in MS patients.
Main Methods:
- Detection of autoantibodies (IgG and IgM) against proteasome and its subunits in serum and cerebrospinal fluid (CSF) of MS patients using various immunological assays.
- Characterization of immunodominant epitopes on proteasomal subunits using recombinant constructs.
- Assessment of peripheral blood mononuclear cell proliferation in response to recombinant proteasomal subunits C2 and C8.
Main Results:
- A significant proportion of MS patients (66% in serum, 61% in CSF) exhibit autoantibodies against the proteasome.
- Specific autoantibodies target proteasomal subunits C2, C8, C9, and C5, with an immunodominant epitope localized on the C-terminus of C2.
- Forty percent of MS patients showed positive T-cell proliferation in response to recombinant proteasomal subunits C2 and C8.
- Anti-proteasome autoantibody prevalence was higher in MS patients compared to those with systemic lupus erythematosus, Sjogren's syndrome, vasculitis, sarcoidosis, and Behcet's disease.
Conclusions:
- Humoral autoreactivity to the proteasome is a common feature in multiple sclerosis.
- Anti-proteasome autoantibodies may serve as a valuable diagnostic or prognostic biomarker for MS.
- The findings suggest a role for proteasome autoimmunity in the pathogenesis of MS and indicate broader immune system abnormalities, including B and T cell dysfunction.